It does appear to indicate a point of disagreement which led to the changes to Board and Management. I guess the two potential outcomes for the FPP delivery platform was an earlier sale or out-licencing during the pre-clinical development phase or a push towards the clinic with potential phase 1 trials for FPP-cargoes.
Whatever the outcome, the science appears to be the big winner. The announcement appears to simply say lets get on with it.
It does appear to indicate a point of disagreement which led to...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
0.040(3.23%) |
Mkt cap ! $746.5M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.29 | $1.25 | $79.39K | 62.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 23727 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.28 | 1942 | 1 |
View Market Depth
| Last trade - 14.40pm 25/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |